Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

RLIP76 in Human Serum in Adults With Rheumatologic Diseases

This study has been withdrawn prior to enrollment.
(Study withdrawn due to lack of staffing resources and subject interest)
Information provided by:
University of North Texas Health Science Center Identifier:
First received: September 29, 2008
Last updated: January 11, 2011
Last verified: January 2011
It is the investigators aim to determine the feasibility of directly detecting anti-RLIP76 auto-antibodies in human serum using prepared RLIP76 antigen peptides in persons with rheumatologic disease and persons without rheumatologic diesease ("healthy subjects").

Carotid Atherosclerosis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Measurement Of RLIP76 Auto Antibodies in Human Serum In Adults With Rheumatologic Diseases.

Further study details as provided by University of North Texas Health Science Center:

Primary Outcome Measures:
  • The focus of the present study is limited to establishing validated protocols for detection of anti-RLIP76 antibodies in human sera. [ Time Frame: three years ]

Estimated Enrollment: 100
Study Start Date: September 2011
Estimated Study Completion Date: September 2011
Estimated Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)

Detailed Description:
This is an exploratory study conducted to see the feasibility of measuring the anti-RLIP76 antibody and to standardize the methods for its measurement. We will perform these studies on blood samples obtained from human subjects after informed concent for blood draw for research purposes is obtained by the Clinical Research Co-ordinator (CRC).

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
The experimental populations subject to study will be 100 outpatients in the rheumatology clinic otherwise undergoing routinely scheduled phlebotomy for standard clinical care purposes.

Inclusion Criteria:

  • Adult (age 18+), non-pregnant subjects with previously diagnosed rheumatologic disease will be candidates for the study.

Exclusion Criteria:

  • Children, pregnant women, prisoner, persons with any medical condition that precludes phlebotomy, and patients unwilling or unable to provide consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00861159

United States, Texas
University of North Texas Health Science Center
Fort Worth, Texas, United States, 76109
Sponsors and Collaborators
University of North Texas Health Science Center
Principal Investigator: Sanjay Awasthi, MD University of North Texas Health Science Center
  More Information


Responsible Party: Measurement of RLIP76 Auto Antibodies in Human Serum in Adults with Rheumatologic Disease., University of North Texas Health Science Center Identifier: NCT00861159     History of Changes
Other Study ID Numbers: 2008-31
Study First Received: September 29, 2008
Last Updated: January 11, 2011

Keywords provided by University of North Texas Health Science Center:
RLIP76 Auto Antibodies

Additional relevant MeSH terms:
Carotid Artery Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Immunologic Factors
Physiological Effects of Drugs processed this record on May 25, 2017